Impax cuts 110 jobs in ongoing Rytary fallout
This article was originally published in Scrip
Impax Laboratories has cut 110 jobs, mostly at its Hayward, California manufacturing facility to "reduce expenses and adapt to changing market conditions" – i.e. reconsider the company's budget in light of ongoing efforts to comply with US FDA drug-making standards and resubmit a marketing application for the Parkinson's disease drug Rytary (IPX066).
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.